Pharmacy Pricing: Between Regulations, Pharmacy Margins, and Competition from Drugstores
Fabrice Decroo
Consulting Director
August 21, 2026
In pharmacies, a large portion of the product lineup—reimbursable medications—has a price set by agreement with the CEPS, not by the retail outlet (Art. L162-16-4 CSS). The average gross margin for a pharmacy fell from 29.4% (2023) to 28.3% (2024, USPO). The only real scope for pricing remains in the parapharmacy sector, with margins ranging from 30% to 60%. ⚠️ Regulatory framework subject to change—to be verified with official sources prior to publication.
The pharmacy sector is the retail sector where the first question regarding pricing is not “what price should I set,” but “do I even have control over this price?” A large portion of the pharmacy’s product lineup—reimbursable medications—is structurally beyond the point-of-sale’s commercial control.
This guide carefully establishes this framework, drawing on official sources, before addressing what actually constitutes a business decision at the pharmacy.
A two-tiered catalog—even before we get into the methodology
Before applying any pricing method to a pharmacy, it is essential to make a fundamental distinction: part of the product catalog has prices that are regulated from start to finish, while another part has entirely unregulated prices. Reimbursable medications have a retail price determined by a regulated mechanism: a manufacturer’s price negotiated with the CEPS, a distribution margin set by administrative order, and fixed dispensing fees. Non-reimbursable medications and over-the-counter products, on the other hand, are priced freely.
How Is the Price of a Reimbursable Drug Set?
Legal Framework — To be verified on a case-by-case basis depending on the product. According to Article L162-16-4 of the Social Security Code, the retail price of each reimbursable medication is set by agreement between the company that markets the medication and the Economic Committee for Health Products (CEPS), or, in the absence of an agreement, by a decision of the committee or by order of the relevant ministers (Légifrance).
According to the Leem, the CEPS’s mission is to “set the price of reimbursable drugs at the level that is most advantageous for the community of social security beneficiaries.” The retail price is then supplemented by a sliding-scale distribution margin set by decree, as well as a fixed dispensing fee paid to the pharmacist regardless of the price of the package (introduced in 2016). This mechanism results, with few exceptions, in a single retail price nationwide: it is not a variable that the point of sale adjusts for commercial purposes.
The Economic Reality of the Pharmacy: Margins Under Pressure
28.3% —that is the average overall gross margin for a French pharmacy in 2024 (as a percentage of pre-tax revenue), compared to 29.4% in 2023—a continued decline despite revenue growth (USPO, 2025 Economic Analysis). This paradox can be explained in large part by the structure of the list of reimbursable drugs: a growing share of revenue comes from expensive drugs, which have a lower regulated markup rate due to the degressive nature of the markup scale.
290 pharmacies closed in France in 2024, compared with 197 in 2019, a sign of structural economic pressure on the independent pharmacy model (same source).
The drugstore: the only true arena for pricing decisions
For non-reimbursable medications and all over-the-counter products—including cosmetics, hygiene products, and dietary supplements—prices are set freely, just as in any specialty store.
30–60% —this is the margin range generally observed for non-prescription health products, which are sold at unregulated prices—compared to a significantly lower regulated margin on reimbursable products, particularly for expensive medications, where it hovers around 5% (industry sources from the pharmacy sector, 2024–2025). Over-the-counter products account for approximately 30 to 40% of a high-performing pharmacy’s revenue, but they represent a significantly higher share of total gross profit.
At Booper —the human is in the driver's seat, not an automated system: the goal isn't to apply a one-size-fits-all algorithmic pricing strategy across the entire catalog, but to focus price analysis and management on areas where a business decision actually makes a difference. Booper's price assessment helps identify these actionable areas before implementing a strategy there.
What this means in practice for a pharmacy pricing strategy
- On Reimbursable Services —Focus on the Mix, Not the Price: The Focus Is Shifting Toward Management Efficiency and Compliance.
- For over-the-counter products —apply a rigorous pricing strategy: competitive analysis, differentiated margins, and consistency between brand image and price.
- On governance —never mix the two scopes in the same dashboard.
Mistakes to Avoid in Pharmacy Pricing
- Apply a system of automatic competitive price alignment to reimbursable items, even though the retail price for those items is determined by a regulated mechanism.
- Neglecting the management of the parapharmacy on the grounds that “everything is regulated in the pharmacy.”
- Combining the margin on reimbursable products and the margin on over-the-counter products in a single dashboard.
- Relying on an unverified or outdated regulatory rule: The regulatory framework changes regularly and should be reevaluated.
- Underinvesting in competitive analysis of the drugstore sector, in the face of pressure from specialty retailers and e-commerce.
Pricing in the pharmacy sector isn’t an impossible task—it’s a two-tiered process that must be treated as such. To objectively assess the margin potential within your truly actionable scope, discover our price analysis service.
FAQ
The Economic Committee on Health Products (CEPS) sets or negotiates the manufacturer’s price by agreement with the pharmaceutical company, or, failing that, by ministerial decision or decree (Art. L162-16-4 of the CSS). The pharmacist does not set this price.
The retail price is, with very limited exceptions, a single national price. This should be verified on a case-by-case basis with official sources, depending on the product.
Non-reimbursable medications and the entire range of over-the-counter products, with profit margins that can reach 30 to 60 percent, according to industry sources.
Growth is driven in part by high-priced drugs with low profit margins, while price cuts on reimbursable products are weighing on gross margin in the absence of offsetting factors.
Yes, focused on over-the-counter products and non-reimbursable items. When it comes to reimbursable items, the focus is shifting toward administrative efficiency and managing the product mix.
The price covers the manufacturing and distribution costs. The fee, introduced in 2016, compensates the pharmacist for their services regardless of the price of the package.
Also in this series
- Pricing in the Retail Sector: What's Changing (and What Isn't)
- Industrial B2B Pricing in Distribution: When Prices Are Still Negotiated Line by Line
Sources: Légifrance, Art. L162-16-4 CSS · Leem · Ameli.fr · USPO, 2025 Economic Analysis.
Lowering a price almost always leads to higher sales—that’s never the issue. The real question is whether the additional volume generates enough profit to offset the profit lost on each unit already sold. The answer depends on two figures that are rarely considered together: the product’s markup rate and its actual price elasticity.
In the retail sector, a product’s profitability is never fully reflected in its selling price. Part of it is determined on the shelf (the front-end margin), while another part is negotiated separately with the supplier, off the sales receipt (the back-end margin). Managing one without the other means managing an incomplete picture of profitability—and often, without realizing it, an underestimated one.
The margin, markup, and margin rate do not measure the same thing, and confusing them distorts all the resulting pricing decisions. Once these definitions and their formulas are established, the real question becomes an operational one: how can you maintain an accurate view of your margin when it changes every week, product by product, rather than recalculating it once a quarter in a spreadsheet?